Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.
Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.
复制标题
DOI:
10.1038/s42003-021-02567-3
复制
发表时间:
2021-09-22
影响因子:
5.9
通讯作者:
Kottmann AH
中科院分区:
文献类型:
--
作者:
Malave L;Zuelke DR;Uribe-Cano S;Starikov L;Rebholz H;Friedman E;Qin C;Li Q;Bezard E;Kottmann AH
L-Dopa induced dyskinesia (LID) is a debilitating side effect of dopamine replacement therapy for Parkinson’s Disease. The mechanistic underpinnings of LID remain obscure. Here we report that diminished sonic hedgehog (Shh) signaling in the basal ganglia caused by the degeneration of midbrain dopamine neurons facilitates the formation and expression of LID. We find that the pharmacological activation of Smoothened, a downstream effector of Shh, attenuates LID in the neurotoxic 6-OHDA- and genetic aphakia mouse models of Parkinson’s Disease. Employing conditional genetic loss-of-function approaches, we show that reducing Shh secretion from dopamine neurons or Smoothened activity in cholinergic interneurons promotes LID. Conversely, the selective expression of constitutively active Smoothened in cholinergic interneurons is sufficient to render the sensitized aphakia model of Parkinson’s Disease resistant to LID. Furthermore, acute depletion of Shh from dopamine neurons through prolonged optogenetic stimulation in otherwise intact mice and in the absence of L-Dopa produces LID-like involuntary movements. These findings indicate that augmenting Shh signaling in the L-Dopa treated brain may be a promising therapeutic approach for mitigating the dyskinetic side effects of long-term treatment with L-Dopa. Lauren Malave et al. examine the impact of sonic hedgehog signaling in the dorsal striatum in L-Dopa induced dyskinesia (LID) animal models. Their results suggest that increasing sonic hedgehog signaling can reduce the severity of LID and abnormal involuntary movements, suggesting future therapeutic approaches to mitigate dyskinetic comorbidities of long-term treatment with L-Dopa.
登录
查看更多内容
影响因子:
16.2
作者:
Chuhma N;Mingote S;Moore H;Rayport S
通讯作者:
Rayport S
影响因子:
13.8
作者:
Arensdorf AM;Marada S;Ogden SK
通讯作者:
Ogden SK
影响因子:
8.8
作者:
Arensdorf AM;Dillard ME;Menke JM;Frank MW;Rock CO;Ogden SK
通讯作者:
Ogden SK
影响因子:
6.1
作者:
DAWSON, VL;DAWSON, TM;WAMSLEY, JK
通讯作者:
WAMSLEY, JK
影响因子:
5.3
作者:
Alcacer, Cristina;Santini, Emanuela;Herve, Denis
通讯作者:
Herve, Denis